Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$21.56
▲ $0.28 (+1.3%)
Market data updated: 09/16 05:21 PM
Fundamentals updated: 09/16/2026
News analyzed: 09/16/2026
Market Cap
$593.23M
Day Range
$21.20 - $21.74
52-Week Range
$13.46 - $31.04
Beta
—
Next Earnings
05.11.2026
FLGT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-1.7% (1Y)
Strengths: 15/27 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 6.48
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$53.32 vs. price $21.56 (-347.3%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
54
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
43
Quality
42
Value
43
Momentum
88
Risk
48
Sentiment
56
Fundamental
35
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Fulgent Genetics, Inc. has centered on its **Q2 2026 earnings performance**, where the company reported a loss and missed revenue expectations. Analysts, including Piper Sandler, maintained a **neutral rating** while raising their price target to $19, citing strategic progress. The earnings call highlighted operational updates, though financial results drew attention to challenges. Overall, discussions focused on **financial results, analyst reactions, and internal strategic developments** amid mixed market sentiment.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Fulgent Genetics, Inc.. News trend score: 56. Reason: 5 of the last 18 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
38
🎯 Conviction (vs. Emotion)
36
Psychology
83
Fundamentals
35
Technical
88
Valuation
43
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+20%
Market Narrative
58
Fundamental Reality
36
Narrative Gap
+22
🧠 StockIQ Psychologist
FLGT’s psychology is dominated by anchoring, as the stock’s proximity to resistance (4.0%) creates a psychological barrier. The narrative-reality gap (11 points) hints at a disconnect between investor perceptions and fundamentals, but weak momentum and neutral RSI (54) temper FOMO. The key question: will traders hold near resistance, or will the gap widen as sentiment diverges further? Low volatility (0.80x ATR) suggests no panic, but the absence of momentum could signal indecision.
Updated: 09/06/2026, 08:06 AM
What could change this?
👥 What the crowd believes
"Fulgent Genetics Q2 results missed estimates due to billing system delays, shares fell 10.6%. Full-year guidance cut"
"Piper Sandler raises price target from $15 to $19 while maintaining Neutral rating"
"Strategic progress amid revenue challenges from billing system delays"
"Strong cash position offers cushion despite revenue misses and guidance cuts"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 3/100
🗣️ Why do they disagree?
This stock splits the historical methodologies into two starkly opposing camps: the value-focused investors overwhelmingly see opportunity, while the growth, market efficiency, and behavioral analysts overwhelmingly dismiss it. Benjamin Graham and his enterprising counterpart, Walter Bagehot, and even Charles Mackay all rate it highly, emphasizing strong fundamentals, liquidity, and the absence of speculative mania—suggesting it meets classic value criteria. In contrast, Fisher, Veblen, and Housel reject it outright, flagging either a lack of growth quality, speculative overreach, or excessive volatility that would test even the most patient investors. The middle-ground thinkers like Marks and Loeb acknowledge some merits but caution against inflated expectations or cyclical risks, while the trend-following and efficiency-based models (Livermore, Schwager, Malkiel/Bogle) outright ignore it, either due to unclear momentum or the belief that passive indexing is superior.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 96
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 68
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 64
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 63
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 57
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 56
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 43
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 40
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 33
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 27
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 21
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 17
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 12
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 3
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 278 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 1 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
40.6%
Operating Margin
-28.2%
Net Margin
-18.8%
EBITDA Margin
-20.8%
ROE
-5.4%
ROA
-5.0%
ROIC
—
EPS
—
Cash
$50.19M
Total Debt
—
Current Ratio
6.48
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$21.56
Estimated Fair Value (DCF)
-$53.32
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-347.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-118.00M | $-108.26M |
| 2 | -3.1% | $-114.31M | $-96.22M |
| 3 | -1.2% | $-112.88M | $-87.17M |
| 4 | 0.6% | $-113.59M | $-80.47M |
| 5 | 2.5% | $-116.43M | $-75.67M |
Base FCF (last actual year)
$-124.21M
Terminal Value
$-1.84B
Present Value of Terminal Value
$-1.19B
Enterprise Value
$-1.64B
Net Debt
$0
Equity Value
$-1.64B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$36.13
Tangible Book Value per Share (Tangible NAV)
$30.99
Sentiment based on basic keywords (not AI) — 5 positive, 9 neutral, 4 negative out of the last 18 articles.
Motley Fool · 8.8.2026
SeekingAlpha · 7.8.2026
Simply Wall St. · 6.8.2026
Benzinga · 4.8.2026
Moby · 31.7.2026
SeekingAlpha · 31.7.2026
Benzinga · 31.7.2026
GuruFocus.com · 31.7.2026
MarketBeat · 30.7.2026
Zacks · 30.7.2026
ChartMill · 30.7.2026
Business Wire · 30.7.2026
Benzinga · 30.7.2026
Benzinga · 30.7.2026
Benzinga · 30.7.2026
Business Wire · 9.7.2026
Simply Wall St. · 25.6.2026
Simply Wall St. · 7.6.2026
Fulgent Genetics, Inc. (FLGT) currently has a StockIQ AI score of 54/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
FLGT currently scores 54/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, FLGT's estimated fair value is -$53.32, which is 347.3% below the current price of $21.56. This is one valuation model among several signals in the fair-value category, not a price target.
FLGT's technical score is 88/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 6.48; Price is above the 50-day average; Price is above the 200-day average.
Based on the real signals StockIQ computed: Estimated fair value: -$53.32 vs. price $21.56 (-347.3%); Operating margin: -28.2% (negative); Net margin: -18.8% (negative).
StockIQ has no recorded dividend payment history for FLGT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Gao Hanlin | Open Market Sale | 2.9.2026 | 1,673 | -1,673 | $19.66 |
| Xie Jian | Open Market Sale | 2.9.2026 | 2,127 | -2,127 | $19.66 |
| Hsieh Ming | Tax Withholding in Shares | 1.9.2026 | 4,392 | -4,392 | $19.59 |
| Kim Paul | Tax Withholding in Shares | 1.9.2026 | 2,087 | -2,087 | $19.59 |
| Xie Jian | Open Market Sale | 27.8.2026 | 1,193 | -1,193 | $19.91 |
| Gao Hanlin | Open Market Sale | 27.8.2026 | 939 | -939 | $19.91 |
| Gao Hanlin | Open Market Sale | 27.8.2026 | 987,790 | -939 | $19.91 |
| Xie Jian | Open Market Sale | 27.8.2026 | 362,051 | -1,193 | $19.91 |
| Kim Paul | Tax Withholding in Shares | 26.8.2026 | 1,168 | -1,168 | $19.81 |
| Hsieh Ming | Tax Withholding in Shares | 26.8.2026 | 2,949 | -2,949 | $19.81 |
| Kim Paul | Tax Withholding in Shares | 26.8.2026 | 358,630 | -1,168 | $19.81 |
| Hsieh Ming | Tax Withholding in Shares | 26.8.2026 | 890,344 | -2,949 | $19.81 |
| Kim Paul | Tax Withholding in Shares | 26.7.2026 | 2,747 | -2,747 | $19.67 |
| Xie Jian | Tax Withholding in Shares | 26.7.2026 | 4,361 | -4,361 | $19.67 |
| Gao Hanlin | Tax Withholding in Shares | 26.7.2026 | 1,645 | -1,645 | $19.67 |
| Kim Paul | Tax Withholding in Shares | 26.7.2026 | 359,798 | -2,747 | $19.67 |
| Gao Hanlin | Tax Withholding in Shares | 26.7.2026 | 988,729 | -1,645 | $19.67 |
| Xie Jian | Tax Withholding in Shares | 26.7.2026 | 363,244 | -4,361 | $19.67 |
| Gao Hanlin | Open Market Sale | 2.6.2026 | 1,688 | -1,688 | $17.89 |
| Xie Jian | Open Market Sale | 2.6.2026 | 2,146 | -2,146 | $17.89 |
| Gao Hanlin | Open Market Sale | 2.6.2026 | 990,374 | -1,688 | $17.89 |
| Xie Jian | Open Market Sale | 2.6.2026 | 367,605 | -2,146 | $17.89 |
| Hsieh Ming | Tax Withholding in Shares | 1.6.2026 | 4,392 | -4,392 | $18.09 |
| Kim Paul | Tax Withholding in Shares | 1.6.2026 | 2,087 | -2,087 | $18.09 |
| Kim Paul | Tax Withholding in Shares | 1.6.2026 | 362,545 | -2,087 | $18.09 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,368,385 shares short as of 2026-08-31 · vs. 2,565,192 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
46.1% of trading volume this week was short selling, vs. 37.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology